The effect of inhibition of glycogen phosphorylase by 1,4-dideoxy-1,4-imino-D-arabinitol on rates of gluconeogenesis, gluconeogenic deposition into glycogen, and glycogen recycling was investigated in primary cultured hepatocytes, in perfused rat liver, and in fed or fasted rats in vivo clamped at high physiological levels of plasma lactate. 1,4-Dideoxy-1,4-imino-D-arabinitol did not alter the synthesis of glycerol-derived glucose in hepatocytes or lactate-derived glucose in perfused liver or fed or fasted rats in vivo. Thus, 1,4-dideoxy-1,4-imino-D-arabinitol inhibited hepatic glucose output in the perfused rat liver (0.77 ؎ 0.19 versus 0.33 ؎ 0.09, p < 0.05), whereas the rate of lactate-derived gluconeogenesis was unaltered (0.22 ؎ 0.09 versus 0.18 ؎ 0.08, p ؍ not significant) (1,4-dideoxy-1,4-imino-D-arabinitol versus vehicle, mol/min * g). Overall, the data suggest that 1,4-dideoxy-1,4-imino-D-arabinitol inhibited glycogen breakdown with no direct or indirect effects on the rates of gluconeogenesis. Total end point glycogen content (mol of glycosyl units/g of wet liver) were similar in fed (235 ؎ 19 versus 217 ؎ 22, p ؍ not significant) or fasted rats (10 ؎ 2 versus 7 ؎ 2, p ؍ not significant) with or without 1,4-dideoxy-1,4-imino-D-arabinitol, respectively. The data demonstrate no glycogen cycling under the investigated conditions and no effect of 1,4-dideoxy-1,4-imino-D-arabinitol on gluconeogenic deposition into glycogen. Taken together, these data also suggest that inhibition of glycogen phosphorylase may prove beneficial in the treatment of type 2 diabetes.Inappropriately elevated endogenous glucose production is established as a major contributor to the fasting hyperglycemia observed in patients with type 2 diabetes (1-4). Endogenous glucose production (EGP) 1 arises via the gluconeogenic pathway or from the breakdown of glycogen. Therefore, inhibition of glycogenolysis and of gluconeogenesis have been regarded as potential therapeutic approaches in the search for novel antihyperglycemic drugs for the treatment of this disease (5-10). Glycogen phosphorylase is the rate-controlling enzyme of the glycogenolytic pathway (11), and we have previously reported that 1,4-dideoxy-1,4-imino-D-arabinitol (DAB) is a potent inhibitor of glycogen phosphorylase and glycogen breakdown with an associated anti-hyperglycemic effect (9, 12, 13).Controversy exists regarding the relative contribution of gluconeogenesis and glycogenolysis to total glucose production in the normal situation and especially in type 2 diabetes (3, 4, 14 -16), mainly due to technical difficulties in the quantification of gluconeogenesis (17). Also, the existence of a hepatic "interregulatory" mechanism has been proposed (18 -23), further confounding the interpretation of the relative importance of gluconeogenesis and glycogenolysis in hepatic glucose and glycogen metabolism. Thus, basal EGP remained constant when gluconeogenesis was acutely increased by infusion of gluconeogenic precursors (18,22,23) or when gluconeogenesis was inhibited wi...